-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
April 29, NMPA official website shows, Ka Ruili natalizumab new indications approved on the market, use for previously treated with second-line chemotherapy, disease progression and after more or intolerable advanced nasopharyngeal carcinoma patients
.
At the 2020 ESMO conference, Hengrui announced the clinical results of the national multi-center, single-arm clinical trial CAPTAIN study
.
The trial included 156 patients with recurrent/metastatic nasopharyngeal carcinoma who had failed ≥2 lines of treatment
The results of the study with a median follow-up of 9.
2 months showed that the ORR reached 28.
2%, the 12-month DoR rate was 58.
5%, the median PFS was 3.
.
Among the domestically approved PD-1s, only Hengrui and Junshi have reported on the market for nasopharyngeal cancer indications, including third-line and first-line treatments for nasopharyngeal cancer
.
Junshi is slightly faster than Hengrui, and was approved for third-line therapy on February 10 this year
.
Hengrui’s PD-1 indications are reported in China.
The incidence and mortality of nasopharyngeal cancer are significantly higher than the world average.
50% of the world’s nasopharyngeal cancers occur in China
.
Radiotherapy is the main method for the treatment of early-stage nasopharyngeal carcinoma, but about 20-37% of patients will have local recurrence or distant metastasis
.
The treatment options for recurrent or metastatic nasopharyngeal carcinoma are very limited and the prognosis is poor
.
